2nd Sep 2005 15:31
Skyepharma PLC02 September 2005 For Immediate Release 2 September, 2005 DATE OF RELEASE OF INTERIM RESULTS FOR THE SIX MONTHS ENDING 30 JUNE 2005 UPDATE ON FLUTIFORM(TM) NEGOTIATIONS LONDON, UK, 2 September 2005 - SkyePharma plc (LSE: SKP, NASDAQ: SKYE) willannounce its Interim results for the six months ending 30 June 2005 on Wednesday28 September 2005. These results will be the first presented under InternationalFinancial Reporting Standards. SkyePharma announced at the end of April that it had negotiated Heads of Termswith a major global pharmaceutical company for the US rights to Flutiform(TM).SkyePharma has now discontinued contract negotiations with that party. However,as indicated in July, the April announcement created considerable competitiveinterest in acquiring rights to Flutiform(TM). As a result, SkyePharma remainsin active negotiations with several companies, including advanced discussionswith another major global pharmaceutical company for worldwide rights toFlutiform(TM). Michael Ashton, SkyePharma's Chief Executive, said: "Flutiform(TM)'s prospectscontinue to improve as we believe its profile will make it superior to competingproducts in this fast-growing market, already worth more than $5 billion. Anumber of companies remain actively interested in licensing the product, withina variety of commercial structures including the retention of co-promotionrights by SkyePharma. Progress towards filing of Flutiform(TM) remains on trackand Phase III trials are planned to commence early next year. With estimatedpeak sales of Flutiform(TM) well in excess of $1 billion, we remain convinced ofour ability to deliver significant value to our shareholders." For further information please contact:SkyePharma PLC +44 207 491 1777Michael Ashton, Chief Executive OfficerPeter Laing, Director of Corporate Communications +44 207 491 5124Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000Tim Anderson / Mark Court / Rebecca Skye Dietrich Notes for editors: About SkyePharmaSkyePharma develops pharmaceutical products benefiting from world-leading drugdelivery technologies that provide easier-to-use and more effective drugformulations. There are now eleven approved and marketed products incorporatingSkyePharma's technologies in the areas of oral, injectable, inhaled and topicaldelivery, supported by advanced solubilisation capabilities. For moreinformation, visit www.skyepharma.com. About Flutiform(TM)Flutiform(TM) is a fixed-dose combination of the inhaled corticosteroidfluticasone with the long-acting bronchodilator formoterol in an HFA-poweredmetered-dose aerosol inhaler. Flutiform(TM), which is designed for the treatmentof asthma and chronic obstructive pulmonary disease (COPD), has completed PhaseII development. Certain statements in this news release are forward-looking statements and aremade in reliance on the safe harbour provisions of the U.S. Private SecuritiesLitigation Act of 1995. Although SkyePharma believes that the expectationsreflected in these forward-looking statements are reasonable, it can give noassurance that these expectations will materialize. Because the expectations aresubject to risks and uncertainties, actual results may vary significantly fromthose expressed or implied by the forward-looking statements based upon a numberof factors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. Factors that could cause differences between actual results andthose implied by the forward-looking statements contained in this news releaseinclude, without limitation, risks related to the development of new products,risks related to obtaining and maintaining regulatory approval for existing, newor expanded indications of existing and new products, risks related toSkyePharma's ability to manufacture products on a large scale or at all, risksrelated to SkyePharma's and its marketing partners' ability to market productson a large scale to maintain or expand market share in the face of changes incustomer requirements, competition and technological change, risks related toregulatory compliance, the risk of product liability claims, risks related tothe ownership and use of intellectual property, and risks related toSkyePharma's ability to manage growth. SkyePharma undertakes no obligation torevise or update any such forward-looking statement to reflect events orcircumstances after the date of this release. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L